Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
![Annual Report 2022 Annual Report 2022](/fileadmin/_processed_/5/2/csm_Annual-Report-2022_5bbb98ff66.jpg)
Intravacc publishes 2022 annual report
![](/fileadmin/_processed_/9/c/csm_Boston-2023-01_4e2c25d5a5.jpg)
Looking back on a successful Bio International 2023 in Boston!
![](/fileadmin/_processed_/6/9/csm_corporate-4_617bcb2964.jpg)
Meet the new Business Development Team
![](/fileadmin/_processed_/0/b/csm_corporate-11_1415487483.jpg)
Dutch State Announces the Sale of Intravacc B.V. (The Netherlands)
![press 17 press 17](/fileadmin/_processed_/c/1/csm_press-17_6ca077aac8.jpg)
CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccinee
![](/fileadmin/_processed_/b/a/csm_Gonorrhea_Avacc11_588cca11d1.jpg)
Intravacc awarded US$14.6 Million NIH/NIAID contract to develop intranasal gonorrhea vaccine
![](/fileadmin/_processed_/1/1/csm_covid_Avacc10_0efd4ac143.jpg)
Intravacc announces additional favorable preclinical and toxicology data for Avacc 10®, an intranasal SARS-CoV-2 candidate vaccine
![](/fileadmin/_processed_/a/e/csm_ALS_Avacc31_5f899446cb.jpg)
Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant
![Annual Report 2021 Annual Report 2021](/fileadmin/_processed_/d/0/csm_Annual-Report-2021_39c5905fb4.jpg)
Intravacc publishes 2021 Annual Report and announces expansion of its management team and board of directors
![](/fileadmin/_processed_/9/c/csm_Whooping-caugh_Avacc3_465cd51985.jpg)
Intravacc signs an exclusive license agreement with Zhifei Lvzhu Biopharmaceutical to commercialize Avacc 3